These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 25742173)
1. In-vitro activity of avermectins against Mycobacterium ulcerans. Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173 [TBL] [Abstract][Full Text] [Related]
2. Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment. Scherr N; Pluschke G; Thompson CJ; Ramón-García S PLoS Negl Trop Dis; 2015 Aug; 9(8):e0003996. PubMed ID: 26270480 [TBL] [Abstract][Full Text] [Related]
3. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review. Tanywe A; Fernandez RS JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review. Vouking MZ; Tamo VC; Tadenfok CN Pan Afr Med J; 2013 Aug; 15():155. PubMed ID: 24396561 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518 [TBL] [Abstract][Full Text] [Related]
10. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection. Zhang T; Li SY; Converse PJ; Grosset JH; Nuermberger EL PLoS Negl Trop Dis; 2013; 7(12):e2598. PubMed ID: 24367713 [TBL] [Abstract][Full Text] [Related]
11. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy. Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068 [TBL] [Abstract][Full Text] [Related]
13. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556 [TBL] [Abstract][Full Text] [Related]
14. Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease. Warryn L; Pluschke G Chimia (Aarau); 2023 Sep; 77(9):577-581. PubMed ID: 38047833 [TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth. Adusumilli S; Haydel SE BMC Complement Altern Med; 2016 Jan; 16():40. PubMed ID: 26833071 [TBL] [Abstract][Full Text] [Related]
16. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. Arenaz-Callao MP; González Del Río R; Lucía Quintana A; Thompson CJ; Mendoza-Losana A; Ramón-García S PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007126. PubMed ID: 30689630 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic management of Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546 [TBL] [Abstract][Full Text] [Related]
19. In Vitro Activity of Selected West African Medicinal Plants against Mycobacterium ulcerans Disease. Tsouh Fokou PV; Kissi-Twum AA; Yeboah-Manu D; Appiah-Opong R; Addo P; Tchokouaha Yamthe LR; Ngoutane Mfopa A; Fekam Boyom F; Nyarko AK Molecules; 2016 Apr; 21(4):445. PubMed ID: 27089314 [TBL] [Abstract][Full Text] [Related]
20. Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts. Iddrisah FN; Yeboah-Manu D; Nortey PA; Nyarko KM; Anim J; Antara SN; Kenu E; Wurapa F; Afari EA Pan Afr Med J; 2016; 25(Suppl 1):13. PubMed ID: 28149438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]